January 13, 2004

Compounds of the formula (I): ##STR1## wherein R.sup.1, R.sup.2, R.sup.4 and R.sup.13 are as defined or a pharmaceutically or veterinarily acceptable salt or polymorph thereof, or a pharmaceutically or veterinarily acceptable solvate or pro-drug thereof: are potent and selective inhibitors of type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PDE5) and have utility in the treatment of, inter alia, male erectile dysfunction (MED) and female sexual dysfunction (FSD).

12

January 13, 2004

09/685,080

October 6, 2000

514/234.2   514/252.16 514/259.4 544/118 544/262 544/357 546/275.4 548/371.7 548/372.5 548/374.1

C07D   401/12   (20060101)   C07D   401/00   (20060101)   C07D   487/04   (20060101)   C07D   487/00   (20060101)   A61K   31/519   (20060101)   C07D   213/80   (20060101)   C07D   213/00   (20060101)   C07D   231/38   (20060101)   C07D   231/00   (20060101)  

This application is filed claiming priority from co-pending U.S. Provisional Application Nos. 60/168,059, filed Nov. 30, 1999 and 60/231,122, filed Sep. 8, 2000.

Oct 11, 1999 [GB] 9924063 Jul 28, 2000 [GB] 0018656

544/262   544/357   544/118   546/275.4   514/234.2   514/258